V501

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anogenital Human Papilloma Virus Infection

Conditions

Anogenital Human Papilloma Virus Infection, Condyloma Acuminata

Trial Timeline

Nov 20, 2015 → Aug 8, 2018

NCT ID

NCT02576054

About V501

V501 is a phase 3 stage product being developed by Merck for Anogenital Human Papilloma Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02576054. Target conditions include Anogenital Human Papilloma Virus Infection, Condyloma Acuminata.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03493542	Phase 3	Completed	Aug 31, 2018	Oct 30, 2023	Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
NCT02576054	Phase 3	Completed	Nov 20, 2015	Aug 8, 2018	Anogenital Human Papilloma Virus Infection
NCT01544478	Approved	Completed	Nov 25, 2011	Aug 27, 2016	Cervical Cancer

Competing Products

3 competing products in Anogenital Human Papilloma Virus Infection

See all competitors

Product	Company	Stage	Hype Score
Topical NO + Placebo	Kyowa Kirin	Phase 2	52
V501 + Placebo	Merck	Phase 3	77
AP611074 + Placebo	Vaxart	Phase 1/2	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved